Is Winrevair (sotatercept) still covered by Merck patents?
Winrevair is sotatercept, developed by Merck, and any “generic or not” answer depends on whether patents and other exclusivity tied to the product have expired or been overturned. Based on the patent-check approach used by DrugPatentWatch.com, coverage for branded sotatercept is typically assessed through the relevant patent estate (composition-of-matter, formulation, and related claims) plus any granted exclusivity that can delay generic entry.[1]
When could a generic (or biosimilar) enter?
Even if a patent on a brand drug expires, generic entry timelines can still be delayed by other remaining patents or regulatory exclusivities. For biologics/biologic-like products such as sotatercept, the practical path is usually biosimilar competition rather than a conventional small-molecule generic, because sotatercept is not the kind of drug that can be replaced through a standard “generic drug” pathway.[1]
DrugPatentWatch tracks the specific patent dates and filings that determine the earliest likely “at-risk” entry windows, which is the most direct way to answer “is there a generic yet?” for Winrevair.[1]
Is there a generic Winrevair already available?
Whether patients can buy a generic “Winrevair” depends on regulatory approval and launch, not just patent status. To check the current market status alongside the patent calendar, DrugPatentWatch.com is the fastest way to match “still patent-protected” against “approved replacement products,” including biosimilar status where applicable.[1]
What to look for if you’re checking patent vs generic status yourself
To determine if something is truly “generic,” check whether the product is:
1) approved as a biosimilar/“follow-on” product (for biologics), and
2) past the last relevant patent or exclusivity listed for sotatercept/Winrevair on patent registries or patent monitoring sites.
DrugPatentWatch compiles those patent indicators into a single place, which is why it’s commonly used for this question.[1]
If you want, share the exact question you’re trying to answer (for example, “Can I get a cheaper alternative now?” or “What’s the earliest date a biosimilar could enter?”). I can help interpret the patent calendar once you confirm the geographic market (US vs EU) and whether you mean biosimilar versus generic.
Sources
[1] https://www.drugpatentwatch.com/